

CSL Seqirus



AS SEEN ON
FAMILY HEALTH DIARY

FLUCELVAX® QUAD

AVAILABLE HERE

NEW ZEALAND'S FIRST CELL-BASED INFLUENZA VACCINE

Studies have shown
that Flucelvax® Quad
offered greater protection
against the flu.†

**TALK TO YOUR VACCINATOR
ABOUT IT TODAY.
A CHARGE WILL APPLY.**

†Compared to the standard flu vaccine.

Flucelvax® Quad is an inactivated influenza vaccine, prepared in cell cultures. Flucelvax® Quad is an unfunded Prescription Medicine, charges will apply, you will need to pay for this vaccine. Flucelvax® Quad is for the prevention of influenza in adults and children aged 6 months of age and older. Each dose contains 60 micrograms/0.5 mL of surface haemagglutinin and neuraminidase from four influenza virus strains, type A and B. Flucelvax® Quad has risks and benefits. Ask your doctor or healthcare professional if Flucelvax® Quad is right for you. Side effects include injection site reactions such as pain, redness, swelling or formation of hard lumps and bruising; muscle aches or joint pain; flu-like symptoms such as headache, fatigue, fever, chills, cough, sore throat, runny or blocked nose; nausea, vomiting, diarrhoea and loss of appetite. Serious side effects include Guillain-Barré syndrome (feeling weak, numbness and tingling in your limbs). Tell your healthcare professional if you have ever had an allergic reaction to any vaccine or to any of the listed ingredients for Flucelvax® Quad. If you have side effects after being given Flucelvax® Quad, talk to your healthcare professional. Additional product consumer information on Flucelvax® Quad is available from www.medsafe.govt.nz. CSL Seqirus, Auckland on 0800 502 757. Flucelvax® Quad is a registered trademark of Seqirus UK Ltd and its affiliates. Seqirus, Auckland 06/24. NZ-FLU-24-0034. TAPS NP 22001. INSIGHT 13364

CSL Seqirus

CSL Seqirus



DESIGNED TO BE AN EXACT MATCH TO WHO-SELECTED STRAINS¹⁻⁴

Vs standard egg-based vaccine*

FLUCELVAX[®]
QUAD
Produced using cell-based technology

6mth+

For patients 6 months and over.⁵

Up to
15%
greater vaccine effectiveness from 4 consecutive US seasons^{7,6-12}

CONSISTENTLY PROVIDED GREATER PROTECTION[†] against test confirmed influenza in individuals aged 4 years to <65 years⁶⁻¹²



Cell based flu vaccine manufacturing is more environmentally sustainable compared with egg-based vaccine manufacturing¹³⁻¹⁵

254
Million

Over 254 million doses of FLUCELVAX have been distributed worldwide.^{16*}

*Strain match alone may not predict clinical effects. [†]Compared to standard egg-based quadrivalent flu vaccines. *includes both trivalent and quadrivalent doses.

References: 1. Rajaram S et al. Ther Adv Vaccines Immunother.2020;8:2515135520908121. 2. CDC. Cell-based flu vaccines. Available from: www.cdc.gov/flu/prevent/cell-based.htm Accessed Sept 2023. 3. Mabrouk T et al. Dev Biol (Basel). 2002;110:125-134. 4. WHO. Influenza A(H3N2) lineage cell culture-derived CVVs for development and production of vaccines for use in the 2025 SH influenza season; Available from: https://cdn.who.int/media/docs/default-source/influenza/cvvs/cvv-southern-hemisphere-2025/summary_a_h3n2_cvv-cell_sh25_20240927.pdf?sfvrsn=e4cbb2b3_3 Accessed Jan 2025. 5. Flucelvac Data Sheet June 2024. 6. Stein AN, et al. Open Forum Infect Dis. 2024;11(5):ofas175. 7. Stein AN et al. Abstract presented OPTIONS 2024, September 8. Divino V, et al. Vaccine.2020;38:6334-6343. 9. Krishnarajah G, et al. Vaccines (Basel). 2021;9(2):80. 10. Divino V, et al. Open Forum Infect Dis. 2021;9(1):ofab04. 11. Boikos C, et al. Clin Infect Dis.2020;71(10):e665-e671. 12. Boikos C, et al. Vaccines (Basel). 2022;10(6):896. 13. The Dark Side of Your Seasonal Flu Vaccine, and Its Startling Environmental Impact [Internet]. EnGen Bio. 2021. 14. Audsley JM et al. Expert Opin Biol Ther. 2004;4(5):709-717. 15. Ulmer JB et al. Nat Biotechnol. 2006;24(11):1377-1383. 16. Data on File #8. Cumulative doses (to June 2024). Seqirus Inc.

Flucelvac[®] Quad is an unfunded Prescription Medicine. Flucelvac[®] Quad is an inactivated quadrivalent influenza vaccine, prepared in cell cultures as a suspension for injection, in a single-dose glass syringe. **PRESENTATION:** Each dose contains 60 microgram/0.5 mL of surface haemagglutinin and neuraminidase from four influenza virus strains. **INDICATIONS:** For the prevention of influenza caused by Influenza Virus, types A and B, in adults and children 6 months of age and older. **CONTRAINDICATIONS:** Known severe allergic reaction (e.g. anaphylaxis) to a previous influenza vaccination or to any component of the vaccine. **ADVERSE EVENTS: Local** injection site pain, erythema and induration. **Systemic** headache, fatigue, myalgia, irritability, nausea, upper respiratory tract infection and nasopharyngitis. Post-marketing serious adverse events includes hypersensitivity reactions, anaphylactic shock; paraesthesia, Guillain-Barré syndrome; pruritus, urticaria, or non-specific rash; Extensive swelling of injected limb. **PRECAUTIONS:** Postpone immunisation in patients with febrile illness or acute infection. A protective immune response may not be elicited in all vaccine recipients, particularly in immunosuppressed patients. If Guillain-Barré syndrome has occurred within 6 weeks of previous influenza vaccination, the decision to give Flucelvac[®] Quad should be based on careful consideration of the potential benefits and risks. Treatment and supervision for anaphylactic reactions should be available. Co-administration with other vaccines has not been studied. **DOSAGE AND ADMINISTRATION:** By intramuscular injection only. Gently shake to produce a clear to slightly opalescent suspension before use. Store at 2-8°C; do not freeze; protect from light. Before prescribing, review the Flucelvac[®] Quad Data Sheet (June 2024) www.medsafe.govt.nz. Seqirus Auckland, 0800 502 757. Flucelvac[®] Quad is a registered trademark of Seqirus UK Ltd or its affiliates. Date of preparation: Dec 2024. NZ-FLU-24-0033. TAPS DA2414ER, INSIGHT 13362

CSL Seqirus